Journals / Endokrinolojide Yönelişler / 2002 / Cilt: 11 - Sayı: 6

The effect of orlistat (XENICAL) taken with diet on body fat composition and blood lipid levels in adult obese women

Yetişkin obez kadınların tedavisinde diyetle birlikte kullanılan orlistat (XENICAL)'in vücut yağ kompozisyonu ve kan lipid düzeylerine etkisi

Pages
262–268
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Because of decrease in fatt mass was not higher in SG than SG, in order to decrease risk factors of obesity, drug therapy should be applied with a balanced diet with low calory.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study to investigate the effect of orlistat (xenical) together with diet therapy on degree of weight loss, body composition and blood lipid levels.25 obese women without taking any drug or suffering from any illness that can affect their metabolism were included. 9 people in study group (SG) and 16 people in control group (CG) were investigated.
📊
Key Findings & Data:A balanced diet with low calory for losing weight were given to all patients and orlistat (120 mg x 3) to study group.
💡
Conclusion & Impact:Because of decrease in fatt mass was not higher in SG than SG, in order to decrease risk factors of obesity, drug therapy should be applied with a balanced diet with low calory.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study to investigate the effect of orlistat (xenical) together with diet therapy on degree of weight loss, body composition and blood lipid levels.25 obese women without taking any drug or suffering from any illness that can affect their metabolism were included. 9 people in study group (SG) and 16 people in control group (CG) were investigated. At the beginning of study, weight, height, waist and hip circumference, and body composition measurements using bioelectrical impedance analyzer were made. At the same time, blood samples for fasting glucose (FG), insulin, triglycéride (TG), cholesterol (C), HDL, LDL, VLDLC were taken. A balanced diet with low calory for losing weight were given to all patients and orlistat (120 mg x 3) to study group. Every patient was examined for weight loss degree and adaptation to therapy monthly, and all the antropometric and biochemistric measurements were made at the third month. Statistical analysis of results were computed with Mann Whitney U and Wilcoxon tests. Weight loss of the groups during therapy were significant (SG; 10.12±4.32, CG; 6.80±2.27 kg, p=0.032). Difference between TG levels was significant (SG; 9.33± 43.29, CG; 25.25±41.79 mg/di). Difference in Total body water loss was significant (sG; 2.55±2.48, CG; 0.82±2.79 It). Total fat mass loss were 2.55±2.48 in SG and 4.36± 2.78 kg in CG (p=0.846). Total fat free (lean) mass were 4.43±3.04 in SG and 2.40+2.88 kg in CG (p=0.020). While insulin level in CG decreased significantly, it was insignificant in SG (p=0.260). Weight loss and decrease in waist and hip circumferences were significant in both of groups. Although the difference of weight loss was higher significantly in SG, this loss was attributed to decrease in total body water and lean mass also. Besides, adherence to diet therapy in patients taking orlistat was worse than CG. Adherence to diet therapy was better in CG. significant decrease in triguceride and insulin levels in CG were attributed to better adherence to diet when compared to SG. Because of decrease in fatt mass was not higher in SG than SG, in order to decrease risk factors of obesity, drug therapy should be applied with a balanced diet with low calory.

Özet

Bu çalışmada, obez kadınların tedavisinde diyetle birlikte kullanılan Xenical'in zayıflama derecesi, vücut kompozisyonu ve kan lipid düzeylerine etkisinin incelenmesi amaçlanmıştır. Obezitesi nedeniyle polikliniğimize başvuran kadınlardan metabolizmayı etkileyebilecek herhangi bir bozukluğu ya da ilaç kullanma öyküsü olmayan toplam 25 kişi çalışmaya alınmıştır. Çalışma grubunda (ÇG) 9, kontrol grubunda (KG) 16 kişi incelenmiştir. Çalışmanın başlangıcında bütün kadınların ağırlık, boy, be! ve kalça çevresi ölçümleri ile Bioelectrical Impedance Analyzer kullanılarak vücut kompozisyonu ölçümleri yapılmış; açlık kan şekeri (AKS), insulin, trigliserid (TG), kolesterol (C), HDL, L.DL ve VLDLC düzeyleri için kan örnekleri alınmıştır. Bütün hastalara düşük kalorili, dengeli zayıflama diyeti verilmiş, ÇG'na ayrıca Xenical (120 mg x 3) önerilmiştir. Hastalar tedaviye uyumları ve zayıflama dereceleri yönünden ayda bir kez kontrol edilmiş, tedavinin üçüncü ayında antropometrik ve biyokimyasal ölçümler tekrarlanmıştır. Sonuçların istatiksel analizi bilgisayar programında Mann Whitney U ve Willcoxon testleri yapılmıştır. Grupların tedavi süresince kaybettikleri kilo farkları anlamlıdır. (ÇG; 10.12±4.32, KG; 6.80±2.27 kg, p=0.032). TG farkı ÇG; 9.33±43.29, KG; 25;25±41.79 mg/dl olup, anlamlıdır (p=0.027). Toplam vücut su kaybı ÇG; 2.55± 2.48, KG; 0.82±2.79 it olup, fark anlamlıdır (p=0.020). Toplam vücut yağ kitlesi kaybı ÇG; 4.73±3.24, KG; 4.36±2.78 kg, p=0.846; yağsız kitle kaybı ÇG; 4.43±3.04, KG; 2.40±2.88 kg, p=0.020 bulunmuştur, insulin düzeyi KG'nda anlamlı olarak azalırken (p=0.041), ÇG'nda anlamlı azalma saptanmamıştır (p=0.260). Her iki grubunda başlangıca göre ağırlık kaybı, bel ve kalça çevresindeki azalma anlamlıdır. ÇG'nun ağırlık kaybındaki fark anlamlı olarak daha fazla olmakla birlikte, bu kaybın vücut suyu ve yağsız kitlenin de kaybının bir sonucu olduğu saptanmıştır. Ayrıca, Xenical kullanan hastaların diyete uyumlarının daha az olduğu belirlenmiş, KG'nun TG ve insulin düzeylerindeki anlamlı azalmanın diyete uyumlarının daha iyi olması ile ilişkili olduğu düşünülmüştür. Yağ dokusundaki azalma ÇG'nda fazla olmadığına göre, obezitenin risk faktörlerinin azaltılması için ilaç tedavisinin düşük kalorili ve dengeli bir diyetle birlikte uygulanmasının gerekli olduğu sonucuna varılmıştır.

🔖

Cite This Article

Özenoğlu, A., ERDEM, T., CANEROĞLU, N., BOYSAN, Ş. N., CAN, G. (2022). The effect of orlistat (XENICAL) taken with diet on body fat composition and blood lipid levels in adult obese women. Endokrinolojide Yönelişler, Cilt: 11 - Sayı: 6, 262–268. https://ajindex.com/articles/500947

References (15)

  1. Bjorntorp P: Visceral obesity: a "civilisation syndrome". Obes Res 1: 206-22, 1993
  2. Siervogel RM, Wisemandle W, Maynard LM, Guo SS, Chumlea WC, Towne B: Lifetime overweight status in relation to serial changes in body composition and risk factors for cardiovascular disease: The feels longutudinal study. Obes Res 8 (6): 420-30, 2000
  3. Özenoğlu A: Obezitede Medikal Nutrisyon Tedavisi, Dilek Ofset, Istanbul, 2001
  4. Scrimshaw NS, Gleason GR. (eds): RAP Rapid Assesment Procedures. International Nutrition Foundation for Developing Countries, Boston, 25-39, 51-61, 1992
  5. Curry KR, Jaffee A: Nutrition counseling and Communication skils. W.B. Saunders Company, Philadelphia, 55-58, 1998
  6. Kvale S: The interview as a conversation. An introduction to qualitative research interviewing. Sage Publication, Thousand Quaks, 19-37,1996
  7. BeBİS (Beslenme Bilgi Sistemi) Bilgisayar Programı. EbiS (Aim) I. Versiyon, Türkçe adaptasyon editörü: Özenoğlu A. 2002
  8. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J: A health economic model to assess the long-term effects and cost effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 25 (2): 303-8 2002 9. Mooradian AD: Obesity: a rational target for managing diabetes mel- litus. Growth Horm IGF Res 11, Suppl A: S79-83, 2001
  9. Glazer G:Long-terrn pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 13-27; 161 (15): 1814-24, 2001
  10. Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J, Madsbad S: Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 4 (1): 19-28, 2002
  11. Frost G, Lyons F, Bovill-Taylor C, Carter L, Stuttard J, Dornhorst A: Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese. J Hum Nutr Diet 15 (4): 287-95, 2002
  12. Phelan S, Wadden TA: Combining behavioral and pharmacological treatments for obesity. Obes Res 10 (6): 560-74, 2002
  13. Ballinger A, Peikin SR: Orlistat: its current status as an anti-obesity drug.Eur J Pharmacol 12; 440 (2-3): 109-17, 2002
  14. Leong KS, Wilding JP: Obesity and diabetes. Baillieres Best Pract Res Clin Endocrinol Metab 13 (2): 221-37, 1999
  15. Finer N, James WP, Kopelman PG, Lean ME, Williams G: One-year treatment of obesity: a randomized, double-blind, placebo-kontrolled, multicentre study of orlistat, a gastrointestinal